{"filings":[{"id":1113203,"accession_number":"0001104659-26-075211","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2026-06-17T20:59:41+00:00","items":["5.07"],"status":"ready","headline":"MaxCyte stockholders elect three Class II directors and ratify CohnReznick as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Patrick Balthrop, Cynthia Collins, and Stanley Erck elected as Class II directors with 39.8M, 46.9M, and 40.9M votes 'for' respectively.","Broker non-votes totaled 17.8M for each director nominee.","Ratification of CohnReznick LLP as auditor for FY 2026 passed with 70.2M 'for', 46.7K 'against', 30.3K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1084397,"accession_number":"0001104659-26-074594","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2026-06-16T20:21:48+00:00","items":["3.01"],"status":"ready","headline":"MaxCyte regains compliance with Nasdaq $1.00 bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 10, 2026 that closing bid price has been ≥$1.00 for 10 consecutive business days (May 27 – June 9, 2026).","Compliance with Listing Rule 5450(a)(1) is now regained; delisting matter is closed.","Previously disclosed receipt of deficiency notice on March 16, 2026 for bid price below $1.00 for 30 consecutive days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40521,"accession_number":"0001104659-26-059399","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2026-05-12T20:12:55+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MaxCyte Q1 revenue $9.7M (-7% YoY); net loss narrows to $4.8M; board authorizes $10M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core revenue $6.2M (-25% YoY); SPL-related revenue rose to $3.4M from $2.1M.","Net loss improved to $4.8M from $10.3M; EBITDA loss $5.1M vs $11.2M.","Reiterated FY 2026 revenue guidance $30-32M (core $25-27M, SPL ~$5M).","Board authorized $10M share repurchase program over one year.","Cash, equivalents and investments $147.7M as of March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102360,"accession_number":"0001104659-26-036201","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MaxCyte appoints Parmeet Ahuja as CFO effective March 30, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Parmeet Ahuja succeeds Douglas Swirsky, who is transitioning from the role as announced in November 2025.","Ahuja brings over 20 years of finance leadership at Agilent, most recently as VP, Investor Relations.","He will receive an annual base salary of $450,000 and a target cash bonus of 50% of base salary.","Inducement equity: option for 375,000 shares and RSU for 187,500 shares of common stock.","Severance agreement provides for 12 months base salary and COBRA upon change-of-control termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102359,"accession_number":"0001104659-26-033867","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MaxCyte Q4 revenue $7.3M, down 16%; FY2025 revenue $33M; guides FY2026 $30-32M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $7.3M (-16% YoY); Core revenue $6.8M (-22% YoY). Net loss $9.6M.","FY2025 total revenue $33.0M (-15% YoY); Core revenue $29.6M (-9% YoY). Net loss $44.6M.","Cash and investments $155.6M at Dec 31, 2025, vs $190.3M a year earlier.","FY2026 guidance: total revenue $30-32M ($25-27M core, $5M SPL); expects cash ≥$136M.","Ended 2025 with 32 SPLs, 13 clinical programs in clinic, and one commercial program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102358,"accession_number":"0001104659-26-032761","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"MaxCyte receives Nasdaq notice for bid price below $1.00; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price below $1.00 for 30 consecutive days as of March 16, 2026.","Must close at or above $1.00 for 10 consecutive trading days by Sept 14, 2026.","If not cured, may seek 180-day extension by transferring to Nasdaq Capital Market.","Company warns no assurance of regaining compliance or avoiding delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102357,"accession_number":"0001104659-26-002901","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte reports preliminary FY2025 core revenue in-line with guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core revenue Q4 2025 est. $6.6-6.7M; full year $29.5-29.6M.","SPL program-related revenue Q4 $0.4-0.6M; full year $3.3-3.5M.","Cash, equivalents & investments ~$155.6M at Dec 31, 2025.","CEO cites challenging year, cost restructuring, expects revenue growth in H2 2026.","Preliminary unaudited results; audited FY2025 results due March 2026."],"consensus_eps_estimate":-0.0816,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":33026000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118636,"accession_number":"0001104659-25-110375","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MaxCyte Q3 revenue down 16% YoY to $6.8M; reiterates FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.8M (-16% YoY); core revenue $6.4M (-21% YoY).","Net loss $12.4M vs $11.6M loss in Q3 2024; adjusted EBITDA loss $10.0M.","Added 4 new SPL clients in 2025 (latest Moonlight Bio in Oct); total SPLs now 32.","Reiterates FY2025 guidance: core revenue flat/-10% YoY; SPL program revenue ~$5M.","Operational restructuring announced Sep 22 to reduce costs; cash at $158M."],"consensus_eps_estimate":-0.1122,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":25726000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118635,"accession_number":"0001104659-25-107118","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte reports preliminary Q3 2025 revenue of $6.8M, down 16% YoY; reiterates FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.8M, core revenue $6.4M (-21% YoY); adds three new SPL clients including Moonlight Bio.","Gross margin 77%; non-GAAP adjusted gross margin 81% (excl. SPL program revenue and inventory reserves).","Rescheduled Q3 earnings call to Nov 12, 2025 due to impairment testing of goodwill and long-lived assets; no prior quarter impact.","Cash and investments $158.0M at Sept 30, 2025; expects year-end cash $152-155M reflecting restructuring costs.","Reiterates FY2025 core revenue guidance: flat to -10% vs 2024; SPL program-related revenue ~$5M."],"consensus_eps_estimate":-0.1122,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":25726000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135120,"accession_number":"0001104659-25-092162","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"MaxCyte cuts ~34% of workforce, expects $13.6M annual savings; reiterates 2025 revenue outlook.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~34% globally, including EOR arrangements; expects pre-tax cash charges of $2.9M.","Annualized cost savings estimated at $13.6M, beginning in Q4 2025.","Reiterates 2025 core revenue flat to down ~10% YoY; SPL program revenue ~$5M.","Expects year-end cash, equivalents, and investments to be at least $155M.","Implementation substantially complete by November 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135119,"accession_number":"0001558370-25-011056","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MaxCyte CCO Ali Soleymannezhad departs effective August 11, 2025; receives nine-month severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ali Soleymannezhad's employment as Chief Commercial Officer ended on August 11, 2025.","Severance includes base salary for nine months and COBRA contributions during the severance period.","Severance is contingent on execution and effectiveness of a release of claims and continued compliance.","No replacement for the Chief Commercial Officer has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135118,"accession_number":"0001558370-25-010523","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MaxCyte Q2 revenue down 18% YoY; lowers 2025 core revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $8.5M, down 18% YoY; core revenue up 8% to $8.2M.","Net loss $12.4M vs $9.4M loss in Q2 2024; operating expenses $21.2M.","Added two SPL clients in July (Adicet Bio, Anocca AB); total SPL agreements now 31.","Updated FY2025: core revenue flat to -10% YoY; SPL Program-related revenue ~$5M.","Expects year-end cash ≥ $155M; cites customer inventory, reprioritization headwinds."],"consensus_eps_estimate":-0.1054,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":18897000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152099,"accession_number":"0001558370-25-008856","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MaxCyte applies to delist from LSE AIM; Nasdaq listing continues unaffected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Applied to cancel admission of common stock to trading on LSE AIM; delisting effective June 26, 2025.","Last trading day on AIM was June 25, 2025; shares continue trading on Nasdaq under MXCT.","No reason for delisting provided; dual-listing costs or administrative simplification possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152098,"accession_number":"0001558370-25-008730","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 2.95M share increase under MaxCyte 2022 Equity Plan; AIM delisting also approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved Amended 2022 Plan, increasing share reserve by 2,950,000 shares (74.1M for, 6.5M against).","Proposal to cancel admission to AIM London Stock Exchange passed with 82.9M votes in favor.","Elected Class I directors: Maher Masoud (69.8M for), Yasir Al-Wakeel (58.9M), Rekha Hemrajani (59.1M).","Ratified CohnReznick LLP as independent auditor for fiscal year 2025 (87.0M for).","Adjournment proposal deemed moot as all other proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152097,"accession_number":"0001558370-25-006739","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MaxCyte Q1 2025 revenue down 8% to $10.4M; reiterates FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $10.4M (-8% YoY); core revenue $8.2M (+1%); SPL program revenue $2.1M (-32%).","Net loss $10.3M vs $9.5M in Q1 2024; cash $174.7M as of March 31, 2025.","Added one SPL client (TG Therapeutics); total active SPLs now 29.","Reiterates FY2025: core revenue growth 8-15%, SPL program revenue ~$5M, ending cash ~$160M.","Integration of SeQure Dx ongoing; management cites robust SPL pipeline."],"consensus_eps_estimate":-0.0816,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":10390000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170914,"accession_number":"0001558370-25-002708","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MaxCyte Q4 core revenue +20%, total rev -45% on milestone comp; FY2025 core growth 8-15%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 total revenue $8.7M (-45% YoY); core revenue ex-milestones $8.6M (+20%); net loss $10.6M vs $5.3M.","FY2024 total revenue $38.6M (-6%); core revenue $32.5M (+9%); gross margin 82%; net loss $41.1M vs $37.9M.","Ended 2024 with $190.3M cash; 28 active SPLs (up from 23), 18 clinical SPL programs, 1 commercial.","2025 guidance: core revenue growth 8-15% (incl SeQure Dx); SPL rev ~$5M; cash target $160M year-end.","Signed record six SPLs in 2024; added TG Therapeutics early 2025; SeQure Dx acquisition integrated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170913,"accession_number":"0001558370-25-000526","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MaxCyte acquires SeQure Dx for $4.5M cash; adds gene-editing safety assessment services","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Initial consideration $4.5M in cash; up to $2.5M additional contingent on revenue targets.","SeQure reported ~$1.7M revenue and ~$6.5M loss (Jan–Nov 2024 unaudited); net assets $0.7M.","Acquisition expected to be accretive to MaxCyte's revenue growth; expands cell/gene therapy offerings.","SeQure specializes in on-target and off-target editing assessments for viral and non-viral modalities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170912,"accession_number":"0001558370-25-000151","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte reports preliminary FY2024 core revenue $32.2M-$32.4M, up 8-9% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 core revenue expected $8.3M–$8.5M vs $7.2M in Q4 2023.","Full-year core revenue $32.2M–$32.4M, up 8–9% from $29.8M in FY2023.","Cash and investments ~$190M at Dec 31, 2024, above updated guidance of $185M.","Added six SPL customers in 2024; supported launch of first FDA-approved non-viral gene-edited cell therapy.","Audited FY2024 results expected in March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":38627000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187885,"accession_number":"0001558370-24-016493","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MaxCyte board member Art Mandell retires effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Art Mandell retired from MaxCyte's board effective Dec 31, 2024; no disagreement with company cited.","Mandell served on board since 2006; board will have nine directors post-retirement.","Patrick Balthrop appointed chairman of Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187884,"accession_number":"0001558370-24-016085","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"MaxCyte cuts 15% workforce, raises 2024 core revenue growth guidance to 6-8%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction of 21 positions (~15% of global workforce) approved December 4, 2024.","Pre-tax charges of ~$0.8M, primarily in Q4 2024; ~$0.3M cash expenditures.","Annualized cost savings of ~$5.8M expected from January 2025.","Raises full-year 2024 core revenue guidance to 6-8% growth vs 2023; affirms SPL revenue ~$6M.","Employee count expected to end 2024 at 116, down from 143 at end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187883,"accession_number":"0001558370-24-014641","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MaxCyte Q3 core revenue up 23% YoY to $8.1M; net loss $11.6M; guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 revenue $8.2M (+2% YoY); core business revenue $8.1M (+23% YoY) driven by cell therapy growth of 39%.","Net loss of $11.6M vs $11.3M in Q3 2023; EBITDA loss $13.0M; stock-based comp $3.4M.","Signed 6 new SPL clients YTD, including Kamau, Legend Biotech, Be Bio; total SPL partners now 29.","Full-year core revenue guidance raised to at least 5% growth; SPL program revenue affirmed at ~$6M.","Cash and investments $196.6M at Sep 30; expects to end 2024 with ~$185M; evaluating potential AIM listing cancellation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":29934000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187882,"accession_number":"0001558370-24-013318","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MaxCyte appoints Cynthia Collins to Board; board expands to 10 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cynthia Collins appointed as Class II director effective Oct 14, 2024; board expands from 9 to 10.","Collins to serve on Compensation Committee; receives 97,698 stock options (3-yr vest) and 51,679 RSUs (1-yr vest).","Over 40 years biotech experience, including CEO of Editas Medicine; boards of Poseida (PSTX), Certara (CERT), and others.","Disclosure notes past directorship at DermTech (OTC:DMTKQ) which filed Chapter 11 in June 2024; no other regulatory issues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204404,"accession_number":"0001558370-24-011088","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MaxCyte Q2 revenue up 15% to $10.4M; core revenue down 9% to $7.6M; SPL revenue jumps 279%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $10.4M (+15% YoY); core business revenue $7.6M (-9% YoY); SPL program-related revenue $2.9M (+279% YoY).","Net loss narrowed to $9.4M from $10.5M in Q2 2023; EBITDA loss $10.9M vs $12.0M.","Signed five new SPLs YTD including Legend Biotech (May) and Be Biopharma (Mar); total SPL partners now 28.","Ended Q2 with $199.8M cash; now expects FY2024 ending cash at least $180M, up from prior $175M guidance.","Raised FY2024 SPL revenue guidance to ~$6M; core business revenue guidance reaffirmed flat to 5% growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":21770000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221169,"accession_number":"0001558370-24-009097","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"MaxCyte stockholders approve 2.3M share increase to equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2022 Equity Incentive Plan increasing authorized shares by 2,300,000.","Plan Amendment passed with ~58.7M votes for, ~10.8M against, ~330K abstentions.","All three board nominees (Brooke, Johnston, Douglas) elected; CohnReznick ratified as auditor.","Amended and Restated 2022 Plan, with details on share counting and award types, filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221168,"accession_number":"0001558370-24-007051","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MaxCyte Q1 revenue $11.3M (+32% YoY); updates 2024 SPL guidance to ~$5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $11.3M, up 32% YoY; core revenue $8.2M, up 5%.","SPL program-related revenue $3.2M, up 292% YoY; four new SPLs signed YTD including Be Biopharma.","Net loss $9.5M vs $10.9M in Q1 2023; EBITDA loss $11.2M.","2024 guidance: core revenue flat to 5% growth; SPL revenue expected ~$5M (increase).","Cash and investments $202.5M at March 31; expects year-end cash at least $175M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":11342000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240746,"accession_number":"0001558370-24-002986","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte Q4 revenue $15.7M (+26% YoY) but core down 32%; net loss $5.3M; reiterates 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $15.7M (+26% YoY); core business revenue $7.2M (-32%); SPL program-related $8.5M (+359%).","Full year 2023 revenue $41.3M (-7% YoY); net loss $37.9M vs. $23.6M loss in 2022.","Cash, equivalents and investments $211.2M at Dec 31, 2023; expects ~$175M at end of 2024.","23 active SPLs at year-end, 3 more signed in Jan 2024 (now 26); 16 licensed clinical programs.","2024 guidance: core revenue flat to +5% YoY; SPL program-related ~$3M; excludes CASGEVY milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240745,"accession_number":"0001558370-24-002480","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte provides FY2024 guidance: core flat to +5%; FY2023 prelim core down 25% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 prelim total revenue $41.1-$41.3M (vs $44.3M in 2022); core revenue $29.6-$29.8M (vs $39.6M), down ~25%.","SPL program-related revenue was ~$11.4M in FY2023 (vs $4.6M in 2022), driven by licensing.","FY2024 guidance: core flat to +5%; SPL ~$3M; outlook does not include CASGEVY royalties.","Year-end 2023 cash & investments ~$210M; expects to end 2024 with ~$175M.","Already signed three SPLs in 2024; presenting at Cowen conference March 5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240744,"accession_number":"0001558370-24-000593","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MaxCyte announces departure of Chief Scientific Officer Cenk Sumen","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cenk Sumen, Ph.D., ended employment as Chief Scientific Officer on January 23, 2024.","He will receive 9 months of base salary and COBRA continuation under his severance agreement.","Sumen will remain on MaxCyte's Scientific Advisory Board.","Severance benefits are contingent on execution of a release of claims agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240743,"accession_number":"0001558370-24-000136","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte reports prelim Q4 total revenue $15.5-15.7M, core down YoY; FY total revenue $41.1-41.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 total revenue expected $15.5-15.7M (Q4 2022: $12.4M); core revenue $7.0-7.2M (down from $10.6M) and SPL revenue ~$8.5M (up from $1.9M).","FY 2023 total revenue expected $41.1-41.3M (FY 2022: $44.3M); core revenue $29.6-29.8M (down from $39.6M), SPL ~$11.4M (up from $4.6M).","Cash, equivalents and investments ~$210M as of Dec 31, 2023.","Management cited Vertex CASGEVY FDA approval as milestone validating platform; core revenue decline reflects cell therapy industry headwinds.","Results are preliminary, unaudited; audited statements expected in March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":41288000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258249,"accession_number":"0001558370-23-019718","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MaxCyte CEO Doug Doerfler retires; Maher Masoud appointed CEO; SPL revenue guidance raised to at least $10M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Doug Doerfler retires as President and CEO effective Dec 31, 2023; remains as advisor.","Maher Masoud, EVP Global Business Development & Chief Counsel, becomes President & CEO on Jan 1, 2024; also joins Board.","Masoud's base salary raised to $590,000 (from $412,500); target bonus 60% of base; receives 400,000 share option grant.","2023 core business revenue guidance reiterated at $28-30M; SPL program revenue now expected at least $10M (above prior guidance).","Doerfler gets 18 months base salary severance, 18 months COBRA, 2023 bonus, and monthly $10K consulting fee for up to 20 hrs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258248,"accession_number":"0001558370-23-018276","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte Q3 revenue down 25% to $8.0M, net loss widens; FY guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $8.0M (-25% YoY); core business revenue $6.6M (-33%).","Net loss $11.3M vs $6.4M loss in Q3 2022; EBITDA loss $12.9M vs $7.1M.","Cell therapy revenue $4.7M (-40%); drug discovery $1.9M (-5%).","FY2023 guidance reaffirmed: total $34-36M, core $28-30M, SPL ~$6M.","Cash & investments $208.7M; expect ~$200M year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":25623400.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258247,"accession_number":"0001558370-23-016235","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte preliminary Q3 revenue $7.8-8.0M; cuts FY2023 revenue guidance to $34-36M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue expected $7.8-8.0M, down 25-27% YoY; core revenue $6.4-6.6M, down 33-35% YoY.","FY2023 total revenue guidance reduced to ~$34-36M; core revenue guidance lowered to $28-30M.","SPL program-related revenue Q3 $1.4M vs $0.8M YoY; full-year SPL guidance unchanged at ~$6M.","Company cites depressed cell and gene therapy funding, customer inventory, and elongation of preclinical activity.","Ending cash expected ~$200M, unchanged from initial 2023 outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":25623400.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275555,"accession_number":"0001558370-23-014270","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte Q2 revenue down 6% YoY, core revenue down 14%; expects 2023 core revenue flat to 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $9.0M in Q2 2023 (-6% YoY); core business revenue $8.3M (-14% YoY).","Net loss $10.5M in Q2 vs $8.3M loss in Q2 2022; EBITDA loss $12.0M vs $8.2M.","FY2023 guidance: core revenue now expected comparable to 2022 (flat); SPL program revenue unchanged ~$6M.","Five SPL partnerships signed YTD including Lyell, ViTToria, Prime Medicine; total SPLs at 23.","Cash and investments $216.1M as of June 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":17618900.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293068,"accession_number":"0001104659-23-074068","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"MaxCyte stockholders approve Amended 2022 Equity Incentive Plan, adding ~6.1M new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted 67.4M For, 9.1M Against (92.3% approval) to amend the 2022 Equity Incentive Plan.","Amendment adds 6,069,000 new shares plus shares from prior plans to the share reserve.","Total shares available under the plan will include up to 37.2M shares for Incentive Stock Options.","Three directors elected: Art Mandell, Stanley Erck, Patrick Balthrop; all received majority votes.","Ratification of CohnReznick LLP as independent auditor for FY2023 also approved (83.1M For)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293067,"accession_number":"0001558370-23-009107","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte Q1 revenue $8.6M (-26% YoY), net loss $10.9M; cuts FY23 revenue growth guidance to 8-12%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $8.6M, down 26% YoY; core business revenue $7.8M, down 19%.","Net loss $10.9M vs $4.1M; EBITDA loss $12.2M vs $3.7M.","FY23 total revenue growth guidance lowered to 8%-12%; core revenue growth 5%-10%.","Two new SPL partnerships signed: Walking Fish Therapeutics (May) and Catamaran Bio (Jan).","Douglas J. Swirsky appointed CFO, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":8576300.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313718,"accession_number":"0001104659-23-037467","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MaxCyte names Douglas Swirsky as CFO; salary $425K, option for 350K shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas J. Swirsky appointed CFO and principal accounting officer, effective March 27, 2023.","He receives $425K base salary, 45% target bonus, and a nonqualified stock option for 350K shares at $4.11/share.","Option vests over 4 years: 25% after 12 months, then monthly over 36 months.","Ron Holtz, who served as interim CFO since April 2022, becomes EVP, Administration.","Swirsky previously CFO of AavantiBio and CEO of Rexahn and GenVec; chairman of Cellectar Biosciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313717,"accession_number":"0001558370-23-003872","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte FY2022 total revenue $44.3M (+31% YoY); net loss $23.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $12.4M (+22% YoY); core revenue $10.6M (+4%); gross margin 88%.","Full-year core business revenue $39.6M, up 26%; cell therapy segment grew 33%.","Net loss $23.6M vs $19.1M; EBITDA loss $24.8M; cash and equivalents $227.3M.","18 active SPL partnerships; potential pre-commercial milestones >$1.55B.","2023 guidance: total revenue growth 21-26%, core growth 20-25%, SPL program revenue ~$6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313716,"accession_number":"0001558370-23-002942","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte reports preliminary FY2022 revenue $44.3M (+31% YoY); guides 2023 growth 21-26%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 total revenue ~$44.3M, up 31% from $33.9M in 2021; Q4 revenue ~$12.4M, up 22%.","Installed base >600 instruments (vs >500 end 2021); 18 SPL partnerships at year-end, 19 after Jan 2023.","2023 guidance: total revenue growth 21-26%, core growth 20-25%, SPL program-related revenue ~$6M.","Potential pre-commercial milestones under SPLs >$1.55B; 16 licensed clinical programs in clinic.","SPL program-related revenue in FY2022 was $4.6M vs $2.5M in 2021; Q4 included $1.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332189,"accession_number":"0001104659-22-123467","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MaxCyte appoints Patrick Balthrop as non-executive director; grants 100,000 stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Balthrop appointed as Class II director and member of Nominating and Corporate Governance Committee effective Nov 30, 2022.","Granted 100,000 nonqualified stock options at $5.99/share, vesting over three years with 1/3 after 12 months.","Balthrop has 35+ years in life sciences; former CEO of Luminex, President of Fisher Healthcare, Abbott Laboratories veteran.","No related party transactions or family relationships with existing directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332188,"accession_number":"0001558370-22-017166","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte Q3 revenue up 5% to $10.6M; core business grows 22%; net loss widens to $6.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $10.6M (+5% YoY); core business revenue $9.9M grew 22% led by cell therapy +27%.","Net loss widened to $6.4M from $2.7M; EBITDA loss $7.1M vs $2.4M loss a year ago.","Cash and equivalents $232.9M; operating expenses rose to $17.0M from $11.6M on staffing and R&D.","Reiterated FY2022 guidance: core revenue growth ~30%, SPL program revenue ~$4.0M.","Cell therapy revenue $7.9M (+27%), drug discovery $2.0M (+4%); SPL revenue fell 62% to $0.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":31837900.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349648,"accession_number":"0001558370-22-013073","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte Q2 revenue $9.6M (+35% YoY); raises 2022 core revenue growth guidance to ~30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $9.6M (+35% YoY); core business revenue +45% led by cell therapy +61%.","Net loss $8.3M (vs $4.4M loss Q2 2021); operating expenses $17.2M (up from $10.7M).","Cash & investments $240.9M as of June 30, 2022.","Raised 2022 core revenue growth guidance to ~30%; SPL program-related revenue expected ~$4M.","Signed 17th SPL agreement in July 2022 with LG Chem."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":21195100.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366663,"accession_number":"0001104659-22-076335","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"MaxCyte stockholders approve 2022 equity incentive plan adding ~2M new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted 58.3M for, 8.0M against, 11k abstain to approve the 2022 Equity Incentive Plan.","Plan adds 1,928,000 new shares plus shares rolled over from prior plans; total reserve not specified.","Three directors re-elected: Doug Doerfler, Yasir Al-Wakeel, Rekha Hemrajani.","CohnReznick LLP ratified as auditor for FY2022 with 71.55M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366662,"accession_number":"0001558370-22-007826","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte Q1 revenue $11.6M (+78% YoY); raises 2022 core revenue guidance to at least 25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $11.6M, up 78% YoY; core business revenue $9.6M, up 48% YoY driven by cell therapy customers (+57%).","SPL Program-related revenue $2.0M vs immaterial; total SPLs now 16 with Intima Bioscience addition.","Net loss narrowed to $4.1M from $7.1M; EBITDA loss $3.7M vs $6.4M.","Raises 2022 core revenue guidance to at least 25% growth; reiterates SPL milestone revenue ~$4M.","Cash and investments $246.3M as of March 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":11587300.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366661,"accession_number":"0001104659-22-045082","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2022-04-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"MaxCyte CFO resigns; appoints Ron Holtz as interim CFO; Q1 revenue at least $11M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amanda Murphy resigns as CFO effective April 15, 2022; Ron Holtz (former CFO 2005-2020, CAO) named interim CFO.","Preliminary Q1 2022 revenue at least $11.0M, up 69% YoY from $6.5M.","Core business revenue at least $9.0M vs $6.5M; SPL program revenue $2.0M vs $0.0.","Sean Menarguez promoted to Director, Investor Relations.","Executive search firm Korn Ferry engaged to find a permanent CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386080,"accession_number":"0001558370-22-004073","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte Q4 revenue record $10.2M (+19%), FY2021 $33.9M (+30%); guides 2022 core growth 22-25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 revenue $10.2M (+19% YoY); FY revenue $33.9M (+30% YoY).","Core cell therapy revenue grew 43% in Q4, drug discovery 32%; SPL program revenue $2.5M FY.","Net loss $4.9M Q4, $19.1M FY; EBITDA loss $4.5M Q4, $17.4M FY; stock-based comp $2.4M Q4, $8.0M FY.","2022 guidance: core revenue growth 22-25% YoY, SPL program revenue ~$4M.","SPL partners now 16 covering >95 programs; potential pre-commercial milestones >$1.25B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386079,"accession_number":"0001104659-22-006977","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2022-01-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte preliminary Q4 rev >$10M (+17% YoY); FY rev >$33.7M (+28%); adds 4 SPLs in 2021","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 preliminary revenue >$10.0M (up from $8.5M in Q4 2020); core business revenue grew at least 37%.","Full year 2021 revenue >$33.7M (up from $26.2M in 2020); program-related revenue $2.5M (vs $3.3M in 2020).","Installed base grew to >500 instruments (from >400); 15 SPLs covering >95 programs, over 15% in clinic.","Precommercial milestone potential from SPLs exceeds $1.25B (up from >$950M in 2020).","New SPLs: Nkarta, Myeloid Therapeutics, Celularity, Sana Biotechnology; ExPERT VLx instrument launched."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":33894100.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404002,"accession_number":"0001104659-21-136950","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte Q3 revenue up 50% to $10.1M; raises FY2021 guidance to at least $33M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $10.1M (+50% YoY); net loss ($2.7M) improved from ($3.1M) prior year.","SPL Program-related revenue $2.0M (record quarter) vs $0.3M YoY; 15 SPL agreements now.","FY2021 revenue guidance raised to at least $33M from prior outlook of >$30M.","Gross margin 91% (up from 89%); cash and equivalents $255.9M as of Sept 30.","James Lovgren appointed SVP Global Marketing; previously VP at Berkeley Lights."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":23742100.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404001,"accession_number":"0001104659-21-133041","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MaxCyte stockholders reject 2021 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three director nominees elected: Will Brooke, John Johnston, Richard Douglas.","2021 Equity Incentive Plan failed: 37,190,511 against vs 25,411,382 for.","2021 Employee Stock Purchase Plan approved with 51,840,812 votes for.","CohnReznick LLP ratified as auditor for FY2021 with 64,672,297 votes for.","64.8M shares (64.5% of outstanding) present or represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404000,"accession_number":"0001104659-21-121662","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2021-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MaxCyte Chairman Dr. Thompson not standing for re-election at Oct 29 meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. J. Stark Thompson will not stand for re-election at the Annual Meeting on October 29, 2021.","He will serve as director and Chairman until the meeting; decision not related to any disagreement.","After meeting, board size will be eight members; a new Chairman will be appointed.","Thompson will continue as a consultant; his outstanding stock options will continue to vest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422968,"accession_number":"0001104659-21-116945","cik":1287098,"company_name":"MAXCYTE, INC.","ticker":"MXCT","form_type":"8-K","filed_at":"2021-09-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MaxCyte Q2 revenue up 38% to $7.1M, net loss widens to $4.4M; guides FY2021 revenue ~$30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.1M (+38% YoY); cell therapy ex-SPL $4.8M (+59%), drug discovery $1.8M (+60%).","Net loss $4.4M vs $3.0M; operating expenses $10.7M (+43%) on higher comp and professional costs.","Signed two new SPL agreements with Celularity and Sana Biotechnology for cell therapy platform.","Completed US IPO on Nasdaq raising $201.8M gross proceeds; cash $73.4M at June 30 pre-IPO.","Preliminary FY2021 revenue guidance of approximately $30M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":125867971.3888889,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-17T23:59:59+00:00|422968"}